PT  - JOURNAL ARTICLE
AU  - DIMITRIOS VOMVAS
AU  - GREGORIS ICONOMOU
AU  - EVANTHIA SOUBASI
AU  - MICHAIL LEOTSINIDIS
AU  - HARALABOS P. KALOFONOS
AU  - STAVROULA BERATIS
AU  - DIMITRIOS KARDAMAKIS
AU  - KONSTANTINOS ASSIMAKOPOULOS
TI  - Assessment of Sexual Function in Patients with Cancer Undergoing Radiotherapy – A Single Centre Prospective Study
DP  - 2012 Feb 01
TA  - Anticancer Research
PG  - 657--664
VI  - 32
IP  - 2
4099  - http://ar.iiarjournals.org/content/32/2/657.short
4100  - http://ar.iiarjournals.org/content/32/2/657.full
SO  - Anticancer Res2012 Feb 01; 32
AB  - Aim: The main objective was to delineate the rates and clinical course of sexual function and depression in cancer patients undergoing radiotherapy. Patients and Methods: Forty-eight male and 90 female radiotherapy-naive outpatients with breast or pelvic cancer completed the International Index of Erectile Function (IIEF) or the Female Sexual Function Index (FSFI), and the Hamilton Depression Scale (HDS) prior to (phase 1), at the end of (phase 2) and 12 months after radiotherapy (phase 3). Results: Overall, the majority of patients (93.8% of males and 80% of females) experienced intense sexual dysfunction. At presentation, males reported severe erectile dysfunction that was significantly associated with age. However, only in sexual desire was the difference between baseline and phase 3 significant. In females, an improvement was observed in all parameters of FSFI between phase 1 and 3. Females with stage III disease achieved lower scores in almost all parameters of FSFI than those with stage II. Finally, although a quarter of patients reported elevated depression scores, depression was not related to sexual function. Conclusion: A significant proportion of cancer patients experience intense levels of sexual dysfunction and depression throughout radiotherapy and the subsequent year. Pelvic radiotherapy affected sexual function to a higher degree than did breast radiotherapy.